RCTs are the gold standard for evaluating the risks and benefits of medical therapies in an unbiased and reliable way. Over time, large randomized clinical trials (RCTs) have become increasingly and prohibitively expensive and complex, and most fail to provide enough evidence to adequately inform medical decision-making, in part due to the common problem of small sample sizes. Adoption of an LST design may be appropriate for some RCTs (e.g., moderately sized but clinically important treatment effect or prevalent disease) and would increase efficiency and reduce costs. Large trials are typically not considered simple endeavors due to perceived operational challenges, and sponsors are currently not dedicating a large percentage of resources to conducting LSTs.

Many clinical trial sponsors, investigators, and government agencies think the system of clinical trials in the U.S. could be improved if there were more LSTs that enrolled many (e.g., thousands) patients, had fewer barriers for trial participation, followed a simple and practical protocol, streamlined operational challenges, collected the most relevant data to meet the trial objectives, and used objective measurements and endpoints.

Facilitating the Use of Large Simple Trials (2012-2014)

• To obtain a deeper understanding of stakeholders’ perceived barriers to using LSTs
• To facilitate an informed discussion of practices and challenges in conducting LSTs
• To issue recommendations for future approaches that will facilitate the appropriate and efficient use of LSTs

LSTs will be used more often for appropriate trials conducted for regulatory submissions and other purposes.

• Stakeholder survey
• Expert meeting

Data from the survey and expert meeting indicated experts agreed that trials determining the risk-benefit balance of therapies must have three major features: be larger, simpler, and randomized. The U.S. Food and Drug Administration (FDA) has promoted the use of LSTs and issued a 2012 draft guidance to serve three main functions: 1) Improve the quality of safety assessment without compromising integrity and validity of trial results, 2) Ease the burden on investigators and patients participating in a study, and 3) Lower trial costs by facilitating the increased use of large, simple trials. However, despite the interest of sponsors and support from regulators, the adoption of LSTs has been limited. The main barrier identified to using LSTs was the perception of ongoing regulatory burden, including the concern that regulators will require more granular data after a trial is completed; yet, survey respondents were willing to support simplified trial designs if they allowed for achievement of regulatory goals. Secondary barriers included the following:

• An overly complicated informed consent process
• The desire to acquire as much information as possible from one trial
• The perception that the NIH focuses mainly on basic science
• Cultural barriers and stakeholder desire
• Patient recruitment and compliance
• Lack of harmonization in regulations
• Expensive academic incentives
• Lack of consistency with clinical practice

Because large trials are inherently not simple, experts suggested that it may be more reasonable to consider strategies for streamlining clinical trials, including being more thoughtful about site selection, having a more focused case report form (CRF), streamlining data collection and safety reporting, monitoring and following up more efficiently, and using registries where appropriate. Many of these suggestions can be guided by solutions proposed in the CTTI Quality by Design project. Other suggested approaches are described in the LST publication, and examples of large trials that have been successfully streamlined are included in the Expert Meeting presentations.

Organization affiliations are listed as active affiliations during the project.

*Indicates former project manager, team leader, or team member.